for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kindred Biosciences Inc

KIN.O

Latest Trade

7.81USD

Change

-0.33(-4.05%)

Volume

97,003

Today's Range

7.80

 - 

8.16

52 Week Range

5.96

 - 

13.96

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.14
Open
8.08
Volume
97,003
3M AVG Volume
2.46
Today's High
8.16
Today's Low
7.80
52 Week High
13.96
52 Week Low
5.96
Shares Out (MIL)
39.06
Market Cap (MIL)
318.20
Forward P/E
-5.34
Dividend (Yield %)
--

Next Event

Kindred Biosciences Inc at Stifel Healthcare Conference

Latest Developments

More

Kindred Biosciences Posts Q3 Loss Per Share of $0.39

Kindred Biosciences Says Positive Opinion From CVMP In The EU For Mirataz For Cats Experiencing Poor Appetite And Weight Loss

Kindred Biosciences Awarded Contract By The National Cancer Institute In Support Of The Prevent Cancer Program

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kindred Biosciences Inc

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Industry

Biotechnology & Drugs

Contact Info

1555 Bayshore Hwy Ste 200

+1.650.7017901

https://www.kindredbio.com/

Executive Leadership

Denise M. Bevers

President, Chief Operating Officer, Director

Richard H. Chin

Chief Executive Officer, Director

Wendy Wee

Chief Financial Officer

Hangjun Zhan

Chief Scientific Officer

Ernest B. Mario

Independent Director

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.130

2017

-1.230

2018

-1.600

2019(E)

-1.539
Price To Earnings (TTM)
--
Price To Sales (TTM)
85.61
Price To Book (MRQ)
2.93
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-52.23
Return on Equity (TTM)
-49.19

Latest News

Latest News

BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36

* KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

FDA approves Kindred treatment for problem weight loss in cats

Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

FDA approves Kindred's weight-loss ointment for cats

Kindred Biosciences inc said on Monday the U.S. Food and Drug Administration had approved its topical treatment for unintended weight loss in cats.

BRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement

* KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT - SEC FILING

BRIEF-Kindred Biosciences Receives FDA Approval Of Mirataz For The Management Of Weight Loss In Cats

* KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS

BRIEF-Kindred Biosciences Announces Board Appointments

* KINDRED BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DR. ERNEST MARIO AND DR. JOSEPH MCCRACKEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Kindred Biosciences Q4 Loss Per Share $0.35

* KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Kindred Biosciences Inc Files For Mixed Shelf Of Up To $150 Million

* KINDRED BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text - (http://bit.ly/2risHPv) Further company coverage:

BRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz

* KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™

BRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral

* KINDREDBIO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ZIMETA ORAL FOR FEVER IN HORSES

BRIEF-Kindred Biosciences posts Q3 loss of $0.29 per share

* Kindred biosciences announces third quarter 2017 financial results

BRIEF-Kindred Biosciences Q2 loss per share $0.29

* Kindred Biosciences announces second quarter 2017 financial results

BRIEF-Kindredbio announces proposed public offering of common stock

* Kindredbio announces proposed public offering of common stock

BRIEF-Kindred Biosciences announces initiation of enrollment in pivotal effectiveness trial of zimeta oral for the control of fever in horses

* Kindred Biosciences announces initiation of enrollment in pivotal effectiveness trial of zimeta oral for the control of fever in horses Source text for Eikon: Further company coverage:

BRIEF-Kindred Biosciences Q4 loss per share $0.29

* Kindred biosciences announces fourth quarter and year-end 2016 financial results

BRIEF-Kindred Biosciences to present Zimeta pivotal data at Annual American Association of Equine Practitioners Convention

* Kindred Biosciences to present Zimeta pivotal data at the 62nd Annual American Association of Equine Practitioners Convention

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up